ArticleEuropean radiology2026
Sequential transarterial radioembolization and atezolizumab plus bevacizumab improves survival in advanced hepatocellular carcinoma.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYttrium-90 transarterial radioembolization (TARE) combined with immune checkpoint inhibitors has been investigated as a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC); however, evidence supporting its addition to current standard systemic therapy remains limited. We aimed to compare clinical outcomes in patients with advanced HCC treated with TARE followed by atezolizumab plus bevacizumab (TARE-Atezo/Bev) and Atezo/Bev alone. MATERIALS AND
methodsThis retrospective cohort study included systemic therapy-naïve patients with advanced HCC treated with Atezo/Bev alone or TARE-Atezo/Bev at a single tertiary hospital between 2018 and 2025. Baseline characteristics were adjusted using propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS).
resultsA total of 156 eligible patients were enrolled, including 93 in the Atezo/Bev group and 63 in the TARE-Atezo/Bev group. In the unmatched cohort, median OS was significantly longer in the TARE-Atezo/Bev group than in the Atezo/Bev group (14.1 vs 6.4 months; hazard ratio=0.43, 95% confidence interval = 0.29-0.63; p < 0.001), with consistent results after PSM (p = 0.01) and IPTW (p < 0.001). Although PFS was comparable between groups in the overall cohort, patients with Child-Pugh class A (OS: 14.6 vs 7.1 months; PFS: 7.7 vs 6.3 months) or ALBI grade 1 (OS: 21.4 vs 8.3 months; PFS: 8.1 vs 5.7 months) had significantly longer OS and PFS in the TARE-Atezo/Bev group, with similar results after adjustment.
conclusionsSequential TARE-Atezo/Bev may improve survival compared with Atezo/Bev alone in patients with advanced HCC and well-preserved liver function. KEY POINTS: QuestionThe survival benefit of yttrium-90 TARE followed by Atezo/Bev compared with Atezo/Bev alone remains uncertain given limited evidence in advanced HCC. FindingsTARE followed by Atezo/Bev was associated with significantly longer OS than Atezo/Bev alone, with both OS and PFS improved in patients with advanced HCC and preserved liver function. Clinical relevanceSequential TARE followed by Atezo/Bev may offer a survival advantage in selected patients with advanced HCC, supporting the integration of locoregional and systemic therapies.
Indexed as
Identifiers
42895551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.